| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6017922 | MEDIMMUNE ONCOLOGY | Thermally stable trimetrexates and processes for producing the same |
May, 2018
(5 years ago) | |
Neutrexin is owned by Medimmune Oncology.
Neutrexin contains Trimetrexate Glucuronate.
Neutrexin has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Neutrexin are:
- US6017922
Neutrexin was authorised for market use on 17 December, 1993.
Neutrexin is available in injectable;injection dosage forms.
The generics of Neutrexin are possible to be released after 18 May, 2018.
Drugs and Companies using TRIMETREXATE GLUCURONATE ingredient
Market Authorisation Date: 17 December, 1993
Treatment: NA
Dosage: INJECTABLE;INJECTION
More Information on Dosage
NEUTREXIN family patents
